An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 16, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Renal Cell CarcinomaMelanomaLung Cancer
Interventions
DRUG

Infliximab + Prednisone

Prednisone dose will be decreased every 3 days for 18 days

DRUG

Methylprednisolone + Prednisone

Prednisone dose will be decreased every 4 days for 40 days

Trial Locations (10)

10016

NYU Langone Medical Center, New York

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

40202

University of Louisville, Louisville

48109

University of Michigan, Ann Arbor

80045

University of Colorado Cancer Center, Aurora

84112

Huntsman Cancer Institute at The University of Utah, Salt Lake City

87131

Local Institution, Albuquerque

90024

University of California Los Angeles, Los Angeles

30322-1013

Winship Cancer Institute, Emory University, Atlanta

07962

Atlantic Health System, Morristown

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02763761 - An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | Biotech Hunter | Biotech Hunter